

## General FAQ

### 1. *What is the Cancer Knowledgebase (CKB)?*

CKB, powered by Genomenon, is the standard in evidence-based interpretation of complex cancer genomic profiles. It is a professionally curated, up-to-date knowledgebase for interpreting complex cancer genomic profiles and connecting variants to available clinical trials and therapies. CKB contains information on gene variants, FDA drug labels, targeted therapies, and clinical trials related to more than 2,000 genes. The standardization protocols and sophisticated search capabilities allow users to navigate increasingly complex data and investigate clinically relevant genomic variants to help identify opportunities to advance cancer research, design clinical trials, and determine the best treatment options for every patient.

### 2. *Can you describe the key competitive advantages of CKB?*

Unlike alternative approaches, CKB is:

- **More Comprehensive:** Contains evidence-based information on variants, FDA drug labels, targeted therapies, preclinical and clinical evidence, and clinical trials related to more than 2,000 genes.
- **Professionally curated:** A dedicated, full-time team of clinical scientists with PhDs and/or MDs.
- **Timely:** Allows for daily updates of new guidelines, genomic modalities, and clinical findings as they emerge.
- **Intuitive:** Includes sophisticated search capabilities that allow users to navigate increasingly complex data, easily investigate clinically relevant variants, and identify particular treatment.
- **Structured:** Uses standardized protocols to enable mapping and identification of clinically relevant variants in a consistent, scalable, and reproducible manner.

### 3. *How does CKB compare to other cancer knowledgebases?*

CKB is a comprehensive, evidence-based resource designed and developed by cancer researchers for cancer researchers. Users can easily search and navigate up-to-date, structured information to help identify opportunities to advance cancer research, design clinical trials, and determine the best treatment options for every patient.

### 4. *What types of customers are using the resource?*

CKB saves time and valuable resources for more than 100,000 clinicians and researchers in more than 165 countries. Customers include:

- |   |  |
|---|--|
| ▪ Clinicians                                  | • Pharmaceutical and biotech organizations |
| ▪ Oncology/translational/academic researchers | • Genetic counselors                       |
| ▪ Companies selling end-to-end solutions      | • Insurance companies                      |

### 5. *What type of information is included in CKB?*

The CKB resource spans more than:

- |                   |  |
|-------------------|--|
| ▪ 2,000 genes     | • 13,000 clinical trials by indication |
| ▪ 45,000 variants | • 4,000 targeted therapies             |

**6. *Where does all this information come from?***

The knowledgebase is curated by our dedicated, full-time team of qualified clinical scientists with PhD and/or MD degrees. The sources used to curate the different types of content found in CKB include published scientific papers indexed in PubMed, published abstracts from professional scientific meetings, FDA drug approvals, professional guidelines, and clinicaltrials.gov. The content is pushed out daily.

**7. *Does CKB cover the complete scientific literature? Does it include information from proprietary or paywalled sources? Are subscriptions a challenge for delivering results to users?***

CKB content curation spans hundreds of scientific journals, many of which require subscriptions for some or all of their peer-reviewed publications. We work closely with our customers to ensure compliance with any necessary copyright licenses for subscription-based content.

**8. *How are customers using CKB?***

Scientists are using the knowledgebase to interpret gene variants, identify the best treatment options for patients, design gene panels, and find relevant clinical trials.

**9. *Can you provide a few examples?***

A peer-reviewed publication in npj Precision Oncology showcased how CKB enabled users to quickly assess mutations that are potentially resistant to targeted therapies, such as specific ALK alterations in the context of an ALK fusion. This information could aid in clinical trial design and analysis, as patients could be stratified by presence or absence of potentially resistant variants.

**10. *How is CKB made available to customers?***

CKB is available in three different versions:

- **CKB FLEX** – Scalable and flexible content for 2,000+ genes .
- **CKB BOOST** – Access 2,000+ genes and related content.
- **CKB CORE** – Free access to a rotating set of 50 genes and related content.

**11. *When was CKB launched?***

We began offering licenses to external customers in 2017. As part of our effort to keep improving the resource, we continue to add new guidelines, genomic modalities, and clinical findings as they emerge. We also have added a number of sophisticated search enhancements and intuitive features to improve the overall user experience.

**13. *Where is the CKB team located?***

The team supporting CKB is part of Genomenon, Inc., headquartered in Ann Arbor, Michigan.



Contact Us to Learn More about  
Genomenon's Somatic Curation Services  
[genomenon.com](https://genomenon.com) | [hello@genomenon.com](mailto:hello@genomenon.com)